BRPI0610722A2 - métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição - Google Patents

métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição

Info

Publication number
BRPI0610722A2
BRPI0610722A2 BRPI0610722A BRPI0610722A BRPI0610722A2 BR PI0610722 A2 BRPI0610722 A2 BR PI0610722A2 BR PI0610722 A BRPI0610722 A BR PI0610722A BR PI0610722 A BRPI0610722 A BR PI0610722A BR PI0610722 A2 BRPI0610722 A2 BR PI0610722A2
Authority
BR
Brazil
Prior art keywords
treating
mrsa
bacterial infection
microbe
ameliorating
Prior art date
Application number
BRPI0610722A
Other languages
English (en)
Inventor
George Y Liu
Victor Nizet
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0610722A2 publication Critical patent/BRPI0610722A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicinal Preparation (AREA)
BRPI0610722A 2005-04-18 2006-04-17 métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição BRPI0610722A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67235905P 2005-04-18 2005-04-18
PCT/US2006/014486 WO2007075186A2 (en) 2005-04-18 2006-04-17 Antimicrobial therapy for bacterial infections

Publications (1)

Publication Number Publication Date
BRPI0610722A2 true BRPI0610722A2 (pt) 2016-11-16

Family

ID=38218400

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610722A BRPI0610722A2 (pt) 2005-04-18 2006-04-17 métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição

Country Status (8)

Country Link
US (2) US8507551B2 (pt)
EP (1) EP1881760A4 (pt)
JP (1) JP2008536933A (pt)
CN (1) CN101198252A (pt)
AU (1) AU2006330064B2 (pt)
BR (1) BRPI0610722A2 (pt)
CA (1) CA2606289C (pt)
WO (1) WO2007075186A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536933A (ja) 2005-04-18 2008-09-11 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細菌感染のための抗菌療法
JP5161872B2 (ja) 2006-05-12 2013-03-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細菌感染に対する抗微生物療法
JP5787341B2 (ja) * 2009-11-19 2015-09-30 国立大学法人 千葉大学 テルペン合成酵素遺伝子のスクリーニング方法
CA2843752A1 (en) * 2011-08-22 2013-02-28 Spectral Platforms, Inc. Rapid detection of metabolic activity
WO2019118515A2 (en) 2017-12-11 2019-06-20 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
CN110305915B (zh) * 2019-06-20 2021-05-14 华南理工大学 一种利用色素阻断剂干扰特氏杜氏藻代谢使其大量积累油脂的方法
JP2022544380A (ja) * 2019-08-09 2022-10-18 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 病原菌を抑制するための組成物及び方法
CN111714490B (zh) * 2020-07-20 2021-07-06 广东工业大学 一种化合物在制备抑制细菌群体感应系统药物中的应用
KR102489659B1 (ko) * 2020-07-20 2023-01-18 경북대학교 산학협력단 암페니콜계 항균제 및 아미노글리코시드계 항균제를 유효성분으로 함유하는 동물용 복합항균제 조성물
CN112574943B (zh) * 2020-12-14 2023-09-01 深圳钰捷生物医学科技有限公司 一种体外模拟皮肤癣菌感染的模型及其建立方法和应用
CN115337320B (zh) * 2022-08-30 2023-08-15 军事科学院军事医学研究院军事兽医研究所 HyG在降低亚胺培南高耐药铜绿假单胞菌MIC的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053789A (pt) * 1964-05-14
US3857934A (en) * 1971-02-02 1974-12-31 Herculite Protective Fab Activated polymer materials and process for making same
CA2159850A1 (en) 1994-11-03 1996-05-04 Yadagiri Pendri Phosphonosulfonate squalene synthetase inhibitor salts and method
US5965553A (en) 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
US5859028A (en) * 1997-04-28 1999-01-12 Potomax Limited Partnership Carotenoid synthesis inhibiting herbicides and fatty acid synthesis inhibiting oxime herbicides as anti-Apicomplexa protozoan parasite agents
US5935808A (en) 1997-07-29 1999-08-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Carotenoid-producing bacterial species and process for production of carotenoids using same
MXPA06001381A (es) * 2003-08-04 2006-05-19 Foamix Ltd Vehiculo de espuma que contiene un gelificante copolimerico anfifilico.
JP2008536933A (ja) 2005-04-18 2008-09-11 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細菌感染のための抗菌療法
JP5161872B2 (ja) 2006-05-12 2013-03-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細菌感染に対する抗微生物療法

Also Published As

Publication number Publication date
US8507551B2 (en) 2013-08-13
US20090042976A1 (en) 2009-02-12
CN101198252A (zh) 2008-06-11
US20130303437A1 (en) 2013-11-14
WO2007075186A2 (en) 2007-07-05
JP2008536933A (ja) 2008-09-11
CA2606289C (en) 2015-03-03
WO2007075186A3 (en) 2007-12-06
EP1881760A4 (en) 2009-03-25
AU2006330064B2 (en) 2012-08-09
CA2606289A1 (en) 2007-07-05
AU2006330064A1 (en) 2007-07-05
EP1881760A2 (en) 2008-01-30

Similar Documents

Publication Publication Date Title
BRPI0610722A2 (pt) métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição
WO2009088549A3 (en) Methods of inhibiting bacterial virulence and compounds relating thereto
WO2008041966A3 (en) Broad spectrum antibacterial compounds
MY147247A (en) Organic compounds and their uses
BRPI0909447A2 (pt) Composição, métodos para tratar um indivíduo humano ou animal em necessidade de tal tratamento e para matar ou inibir o crescimento de microrganismos suscetíveis, e, uso de uma composição
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2010003916A (es) Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BR112012001987A2 (pt) Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase.
WO2007014372A3 (en) Compositions and methods for treating bacteria
WO2007109105A3 (en) Flavivirus inhibition by sultams and related compounds
WO2006063176A3 (en) Inhibition of biofilm formation using bacteriophage
BRPI0717753A2 (pt) Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
TW200734344A (en) Antibacterial agents
WO2007121125A3 (en) Hcv inhibitors
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
EA201100413A1 (ru) Способ лечения бактериальной инфекции
WO2007133712A3 (en) Antimicrobial therapy for bacterial infections
BRPI0618198A2 (pt) métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia
TNSN08496A1 (en) Aminothiazoles and their uses
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
EP3939599A3 (en) Silicate containing compositions and methods of treatment

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20070147383/RJ DE 18/10/2007.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]